Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder
- PMID: 24260145
- PMCID: PMC3829855
- DOI: 10.1371/journal.pone.0079015
Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder
Erratum in
-
Correction: Genetic Polymorphisms in Monoamine Systems and Outcome of Cognitive Behavior Therapy for Social Anxiety Disorder.PLoS One. 2016 Oct 18;11(10):e0165249. doi: 10.1371/journal.pone.0165249. eCollection 2016. PLoS One. 2016. PMID: 27755589 Free PMC article.
Abstract
Objective: The role of genetics for predicting the response to cognitive behavior therapy (CBT) for social anxiety disorder (SAD) has only been studied in one previous investigation. The serotonin transporter (5-HTTLPR), the catechol-o-methyltransferase (COMT) val158met, and the tryptophan hydroxylase-2 (TPH2) G-703T polymorphisms are implicated in the regulation of amygdala reactivity and fear extinction and therefore might be of relevance for CBT outcome. The aim of the present study was to investigate if these three gene variants predicted response to CBT in a large sample of SAD patients.
Method: Participants were recruited from two separate randomized controlled CBT trials (trial 1: n = 112, trial 2: n = 202). Genotyping were performed on DNA extracted from blood or saliva samples. Effects were analyzed at follow-up (6 or 12 months after treatment) for both groups and for each group separately at post-treatment. The main outcome measure was the Liebowitz Social Anxiety Scale Self-Report.
Results: At long-term follow-up, there was no effect of any genotype, or gene × gene interactions, on treatment response. In the subsamples, there was time by genotype interaction effects indicating an influence of the TPH2 G-703T-polymorphism on CBT short-term response, however the direction of the effect was not consistent across trials.
Conclusions: None of the three gene variants, 5-HTTLPR, COMTval158met and TPH2 G-703T, was associated with long-term response to CBT for SAD.
Trial registration: ClinicalTrials.gov (ID-NCT0056496).
Trial registration: ClinicalTrials.gov NCT00564967.
Conflict of interest statement
Figures
References
-
- Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, et al. (1998) Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Archives of General Psychiatry 55: 1133–1141. - PubMed
-
- Furmark T, Carlbring P, Hedman E, Sonnenstein A, Clevberger P, et al. (2009) Guided and unguided self-help for social anxiety disorder: randomised controlled trial. British Journal of Psychiatry 195: 440–447. - PubMed
-
- Hedman E, Andersson E, Ljotsson B, Andersson G, Andersson E, et al. (2012) Clinical and genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta Psychiatr Scand 126: 126–136. - PubMed
-
- Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002) Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59: 877–883. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
